Proc Natl Acad Sci U S A 72(9): 3683-3686
Competitive protein binding assay for methotrexate.
Abstract
A competitive protein binding assay has been developed for methotrexate based on the tight binding of this drug to Lactobacillus casei dihydrofolate reductase (= tetrahydrofolate dehydrogenase; 5,6,7,8-tetrahydrofolate: NADP+ oxidoreductase; EC 1.5.1.3). Free drug may be separated from that bound to reductase by adsorption with dextran--albumin coated charcoal. Scatchard plot analysis of the enzyme--drug interaction confirmed the presence of a single homogeneous class of binding sites with an association constant Ka of 2.1 X 10(8) M-1. This high affinity binding permits detection of methotrexate in the range of 0.3--30 pmol with a coefficient of variation of 15% or less. The predominant circulating folate, 5-methyl tetrahydrofolate, and the clinically useful rescue agent leucovorin (5-formyl tetrahydropteroyl-glutamic acid) do not interfere with the assay, nor does the methotrexate metabolite 4-amino-4-deoxy-10-methylpteroic acid. Assay of clinical samples, including plasma and cerebrospinal fluid, showed close agreement between the previously described enzyme inhibition assay and the more rapid competitive binding method.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (795K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Pinkel D, Hernandez K, Borella L, Holton C, Aur R, Samoy G, Pratt C. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer. 1971 Feb;27(2):247–256. [PubMed] [Google Scholar]
- Jaffe N, Frei E, 3rd, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med. 1974 Nov 7;291(19):994–997. [PubMed] [Google Scholar]
- Kay HE, Knapton PJ, O'Sullivan JP, Wells DG, Harris RF, Innes EM, Stuart J, Schwartz FC, Thompson EN. Encephalopathy in acute leukaemia associated with methotrexate therapy. Arch Dis Child. 1972 Jun;47(253):344–354.[PMC free article] [PubMed] [Google Scholar]
- Frei E, 3rd, Jaffe NJ, Pitman S. Letter: Limitations of methotrexate and citrovorum-factor treatments. N Engl J Med. 1975 Jan 9;292(2):107–108. [PubMed] [Google Scholar]
- Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med. 1973 Oct 11;289(15):770–773. [PubMed] [Google Scholar]
- Zaharko DS, Bruckner H, Oliverio VT. Antibiotics alter methotrexate metabolism and excretion. Science. 1969 Nov 14;166(3907):887–888. [PubMed] [Google Scholar]
- BERTINO JR, FISCHER GA. TECHNIQUES FOR STUDY OF RESISTANCE TO FOLIC ACID ANTAGONISTS. Methods Med Res. 1964;10:297–307. [PubMed] [Google Scholar]
- WERKHEISER WC, ZAKRZEWSKI SF, NICHOL CA. Assay for 4-amino folic acid analogues by inhibition of folic acid reductase. J Pharmacol Exp Ther. 1962 Aug;137:162–166. [PubMed] [Google Scholar]
- Rodbard D, Bridson W, Rayford PL. Rapid calculation of radioimmunoassay results. J Lab Clin Med. 1969 Nov;74(5):770–781. [PubMed] [Google Scholar]
- Waxman S, Schreiber C. Measurement of serum folate levels and serum folic acid-binding protein by 3H-PGA radioassay. Blood. 1973 Aug;42(2):281–290. [PubMed] [Google Scholar]
- BERTINO JR, BOOTH BA, BIEBER AL, CASHMORE A, SARTORELLI AC. STUDIES ON THE INHIBITION OF DIHYDROFOLATE REDUCTASE BY THE FOLATE ANTAGONISTS. J Biol Chem. 1964 Feb;239:479–485. [PubMed] [Google Scholar]
- Otting F, Huennekens FM. TPNH-dependent binding of amethopterin by dihydrofolate reductase from Lactobacillus casei. Arch Biochem Biophys. 1972 Sep;152(1):429–431. [PubMed] [Google Scholar]
- JOHNS DG, BERTINO JR. FOLATES AND MEGALOBLASTIC ANEMIA: A REVIEW. Clin Pharmacol Ther. 1965 May-Jun;6:372–392. [PubMed] [Google Scholar]
- Valerino DM, Johns DG, Zaharko DS, Oliverio VT. Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10 -methylpteroic acid. Biochem Pharmacol. 1972 Mar 15;21(6):821–831. [PubMed] [Google Scholar]
- Bischoff KB, Dedrick RL, Zaharko DS. Preliminary model for methotrexate pharmacokinetics. J Pharm Sci. 1970 Feb;59(2):149–154. [PubMed] [Google Scholar]
- Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. Methotrexate pharmacokinetics. J Pharm Sci. 1971 Aug;60(8):1128–1133. [PubMed] [Google Scholar]
- Wan SH, Huffman DH, Azarnoff DL, Stephens R, Hoogstraten B. Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res. 1974 Dec;34(12):3487–3491. [PubMed] [Google Scholar]
- Levine L, Powers E. Radioimmunoassay for methotrexate. Res Commun Chem Pathol Pharmacol. 1974 Nov;9(3):543–554. [PubMed] [Google Scholar]
- Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest. 1973 Aug;52(8):1804–1811.[PMC free article] [PubMed] [Google Scholar]
- Burchall JJ. Comparative biochemistry of dihydrofolate reductase. Ann N Y Acad Sci. 1971 Nov 30;186:143–152. [PubMed] [Google Scholar]